Armata Pharmaceuticals/$ARMP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Armata Pharmaceuticals
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
Ticker
$ARMP
Sector
Primary listing
AMEX
Employees
60
Headquarters
Website
ARMP Metrics
BasicAdvanced
$108M
-
-$1.35
1.11
-
Price and volume
Market cap
$108M
Beta
1.11
52-week high
$3.14
52-week low
$0.90
Average daily volume
11K
Financial strength
Current ratio
0.063
Quick ratio
0.054
Long term debt to equity
-39.036
Total debt to equity
-200.663
Interest coverage (TTM)
-2.60%
Profitability
EBITDA (TTM)
-33.893
Gross margin (TTM)
-402.88%
Net profit margin (TTM)
-374.30%
Operating margin (TTM)
-514.40%
Revenue per employee (TTM)
$110,000
Management effectiveness
Return on assets (TTM)
-23.35%
Return on equity (TTM)
44.47%
Valuation
Price to revenue (TTM)
15.754
Price to book
-1.56
Price to tangible book (TTM)
-1.48
Price to free cash flow (TTM)
-3.371
Free cash flow yield (TTM)
-29.66%
Free cash flow per share (TTM)
-0.887
Growth
Revenue change (TTM)
84.67%
Earnings per share change (TTM)
-36.88%
3-year revenue growth (CAGR)
8.62%
3-year earnings per share growth (CAGR)
10.03%
What the Analysts think about ARMP
Analyst ratings (Buy, Hold, Sell) for Armata Pharmaceuticals stock.
ARMP Financial Performance
Revenues and expenses
ARMP Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Armata Pharmaceuticals stock?
Armata Pharmaceuticals (ARMP) has a market cap of $108M as of September 17, 2025.
What is the P/E ratio for Armata Pharmaceuticals stock?
The price to earnings (P/E) ratio for Armata Pharmaceuticals (ARMP) stock is 0 as of September 17, 2025.
Does Armata Pharmaceuticals stock pay dividends?
No, Armata Pharmaceuticals (ARMP) stock does not pay dividends to its shareholders as of September 17, 2025.
When is the next Armata Pharmaceuticals dividend payment date?
Armata Pharmaceuticals (ARMP) stock does not pay dividends to its shareholders.
What is the beta indicator for Armata Pharmaceuticals?
Armata Pharmaceuticals (ARMP) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.